Free Trial

Thermo Fisher Scientific (TMO) Stock Forecast & Price Target

Thermo Fisher Scientific logo
$511.83 -2.37 (-0.46%)
(As of 02:21 PM ET)

Thermo Fisher Scientific - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
4
Buy
18

Based on 22 Wall Street analysts who have issued ratings for Thermo Fisher Scientific in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 22 analysts, 4 have given a hold rating, 17 have given a buy rating, and 1 has given a strong buy rating for TMO.

Consensus Price Target

$649.33
26.87% Upside
According to the 22 analysts' twelve-month price targets for Thermo Fisher Scientific, the average price target is $649.33. The highest price target for TMO is $718.00, while the lowest price target for TMO is $575.00. The average price target represents a forecasted upside of 26.87% from the current price of $511.83.
Get the Latest News and Ratings for TMO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Thermo Fisher Scientific and its competitors.

Sign Up

TMO Analyst Ratings Over Time

TypeCurrent Forecast
11/27/23 to 11/26/24
1 Month Ago
10/28/23 to 10/27/24
3 Months Ago
8/29/23 to 8/28/24
1 Year Ago
11/27/22 to 11/27/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
17 Buy rating(s)
17 Buy rating(s)
14 Buy rating(s)
14 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$649.33$649.33$630.41$593.94
Forecasted Upside26.87% Upside17.13% Upside2.82% Upside21.18% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

TMO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TMO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Thermo Fisher Scientific Stock vs. The Competition

TypeThermo Fisher ScientificMedical CompaniesS&P 500
Consensus Rating Score
2.86
2.80
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside27.18% Upside24,797.33% Upside6.96% Upside
News Sentiment Rating
Positive News

See Recent TMO News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/24/2024Sanford C. Bernstein
3 of 5 stars
 Lower TargetMarket Perform ➝ Market Perform$625.00 ➝ $620.00+10.17%
10/24/2024Royal Bank of Canada
4 of 5 stars
 Lower TargetOutperform ➝ Outperform$767.00 ➝ $718.00+27.51%
10/24/2024Stifel Nicolaus
4 of 5 stars
 Lower TargetBuy ➝ Buy$680.00 ➝ $665.00+17.72%
10/24/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$630.00 ➝ $620.00+9.38%
10/24/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
B. Couillard
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$670.00 ➝ $660.00+16.46%
10/24/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$632.00 ➝ $622.00+7.89%
Ever heard of this 8-day bitcoin profit window? (Ad)

Did you know Bitcoin almost always soars higher during an 8-Day Profit Window? Most people have no clue… But for over a year now, some of our top students have had the chance to cash in with some incredible gains during this 8-day window.

10/23/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$620.00 ➝ $610.00+6.63%
10/22/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$656.00 ➝ $686.00+16.92%
10/22/2024Bernstein Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform ➝ Market Perform$565.00 ➝ $625.00+6.30%
10/14/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Clark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$680.00+13.74%
10/1/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Johnson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$680.00+9.93%
9/20/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$650.00 ➝ $670.00+9.13%
9/20/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$655.00 ➝ $680.00+10.95%
9/16/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Leonard
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
9/16/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$600.00 ➝ $675.00+10.44%
7/25/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$650.00 ➝ $660.00+9.56%
6/3/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold ➝ Buy$600.00 ➝ $650.00+14.44%
4/30/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$660.00 ➝ $670.00+17.13%
4/25/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$600.00 ➝ $610.00+6.54%
4/10/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$550.00 ➝ $640.00+10.94%
3/18/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$620.00+6.70%
12/13/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$575.00+15.58%
10/26/2023KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Sector Weight
7/13/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Outperform$620.00+17.89%
2/2/2023Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$620.00 ➝ $630.00+7.26%
2/2/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$690.00 ➝ $711.00+21.05%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 02:48 PM ET.


Should I Buy Thermo Fisher Scientific Stock? TMO Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, November 22, 2024. Please send any questions or comments about these Thermo Fisher Scientific pros and cons to contact@marketbeat.com.

Thermo Fisher Scientific
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Thermo Fisher Scientific Inc.:

  • The company has a strong dividend yield of 0.30%, which can provide a steady income stream for investors. The annualized dividend is $1.56, and the payout ratio is only 9.78%, indicating that the company retains a significant portion of its earnings for growth.
  • Recent analyst ratings show a positive outlook, with 17 analysts assigning a buy rating and one a strong buy rating. This suggests strong confidence in the company's future performance.
  • Thermo Fisher Scientific Inc. has a current stock price around $610.00, which is seen as a reasonable entry point given the company's growth potential and recent price target adjustments by analysts.
  • The company has initiated a stock buyback program, allowing it to repurchase up to 2% of its stock. This often indicates that management believes the stock is undervalued, which can lead to price appreciation.
  • Thermo Fisher Scientific Inc. operates in diverse sectors, including life sciences and biopharma services, which positions it well to benefit from ongoing advancements in healthcare and research.

Thermo Fisher Scientific
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Thermo Fisher Scientific Inc. for these reasons:

  • Despite the positive outlook, some analysts have recently lowered their price targets, indicating potential concerns about short-term performance or market conditions.
  • The stock has a relatively low dividend payout ratio, which, while indicating retained earnings for growth, may also suggest that the company is not prioritizing immediate returns to shareholders.
  • Market volatility can impact the stock price, and with recent adjustments in analyst ratings, there may be uncertainty regarding the company's ability to meet growth expectations.
  • Thermo Fisher Scientific Inc. operates in a highly competitive industry, which can pose risks to market share and profitability, especially if competitors introduce innovative products or services.
  • Economic factors, such as changes in healthcare funding or research budgets, could adversely affect the company's revenue streams and overall financial health.

TMO Forecast - Frequently Asked Questions

According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for Thermo Fisher Scientific is $649.33, with a high forecast of $718.00 and a low forecast of $575.00.

22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Thermo Fisher Scientific in the last twelve months. There are currently 4 hold ratings, 17 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TMO shares.

According to analysts, Thermo Fisher Scientific's stock has a predicted upside of 26.87% based on their 12-month stock forecasts.

Over the previous 90 days, Thermo Fisher Scientific's stock had 1 upgrade by analysts.

Analysts like Thermo Fisher Scientific more than other "medical" companies. The consensus rating score for Thermo Fisher Scientific is 2.86 while the average consensus rating score for "medical" companies is 2.80. Learn more on how TMO compares to other companies.


This page (NYSE:TMO) was last updated on 11/26/2024 by MarketBeat.com Staff
From Our Partners